Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia
Genome Medicine2010Vol. 2(1), pp. 1–1
Citations Over TimeTop 10% of 2010 papers
Nathan Stephens, Iain J. Gallagher, Olav Rooyackers, Richard J.E. Skipworth, Bohao Tan, Troels Marstrand, James A. Ross, Denis C. Guttridge, Lars Lundell, Kenneth C. H. Fearon, James A. Timmons
Abstract
We were able to discover and validate new molecular biomarkers of human cancer cachexia. The exercise activated genes CaMKIIbeta and TIE1 related positively to weight-loss across muscle groups, indicating that this cachexia signature is not simply due to patient inactivity. Indeed, excessive CaMKIIbeta activation is a potential mechanism for reduced muscle protein synthesis. Our genomics analysis also supports the view that the available preclinical models do not accurately reflect the molecular characteristics of human muscle from cancer cachexia patients.
Related Papers
- → Energy metabolism in cachexia(2019)156 cited
- → Unlocking the wasting enigma: Highlights from the 8th Cachexia Conference(2016)32 cited
- → Skeletal muscle wasting after a severe burn is a consequence of cachexia and sarcopenia(2021)10 cited
- → Wasting away: How to treat cachexia and muscle wasting in chronic disease?(2017)3 cited
- → Marihuana for AIDS Wasting(1999)4 cited